This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Springer, B.
Right arrow Articles by Böttger, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Springer, B.
Right arrow Articles by Böttger, E. C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, December 2008, p. 4064-4067, Vol. 46, No. 12
0095-1137/08/$08.00+0     doi:10.1128/JCM.01114-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Tuberculosis Drug Resistance in an Area of Low Endemicity in 2004 to 2006: Semiquantitative Drug Susceptibility Testing and Genotyping{triangledown}

Burkhard Springer,1,2,3 Romana C. Calligaris-Maibach,1,2 Claudia Ritter,1,2 and Erik C. Böttger1,2*

Institut für Medizinische Mikrobiologie, Universität Zürich, Zürich CH-8006, Switzerland,1 Nationales Zentrum für Mykobakterien, Zürich CH-8006, Switzerland,2 Institut für Medizinische Mikrobiologie und Hygiene, Österreichische Agentur für Gesundheit und Ernährungssicherheit, Graz A-8010, Austria3

Received 11 June 2008/ Returned for modification 11 September 2008/ Accepted 3 October 2008

We determined the quantitative levels and the genetic mechanisms of resistance in drug-resistant clinical isolates of Mycobacterium tuberculosis sampled over a period of 3 years (n = 45; 17 of the isolate were multidrug resistant). Our results led us to hypothesize that some strains categorized as resistant to isoniazid, ethambutol, or streptomycin by standard laboratory procedures of in vitro drug susceptibility testing may still respond to a treatment regimen that includes these agents.

* Corresponding author. Mailing address: Institut für Medizinische Mikrobiologie, Universität Zürich, Gloriastrasse 30/32, Zürich CH-8006, Switzerland. Phone: 41 44 634 26 60. Fax: 41 44 634 49 06. E-mail: boettger{at}immv.uzh.ch

{triangledown} Published ahead of print on 15 October 2008.

Journal of Clinical Microbiology, December 2008, p. 4064-4067, Vol. 46, No. 12
0095-1137/08/$08.00+0     doi:10.1128/JCM.01114-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Springer, B., Lucke, K., Calligaris-Maibach, R., Ritter, C., Bottger, E. C. (2009). Quantitative Drug Susceptibility Testing of Mycobacterium tuberculosis by Use of MGIT 960 and EpiCenter Instrumentation. J. Clin. Microbiol. 47: 1773-1780 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»